Home/NurExone Biologic/Eran Ovadya, MBA
EO

Eran Ovadya, MBA

Chief Financial Officer

NurExone Biologic

NurExone Biologic Pipeline

DrugIndicationPhase
ExoPTENAcute Spinal Cord InjuryPreclinical
ExoPTEN‑GlaucomaAcute GlaucomaPreclinical